• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    3/1/24 9:00:00 AM ET
    $BTCY
    $BTTX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTCY alert in real time by email

    ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (NASDAQ:BTTX) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • Better Therapeutics: https://www.redchip.com/assets/access/bttx_access
    • Biotricity: https://www.redchip.com/assets/access/btcy_access

    Frank Karbe, CEO of Better Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Better Therapeutics stands at the forefront of the prescription digital therapeutics (PDT) industry, offering a groundbreaking approach to managing cardiometabolic diseases, a sector marked by substantial patient populations, deep unmet medical needs, and considerable financial burdens on healthcare systems. BTTX's proprietary platform not only addresses these challenges head-on but also aligns seamlessly with existing treatment paradigms that prioritize behavioral change. Better Therapeutics' FDA-authorized product AspyreRx™ demonstrated statistically significant and clinically meaningful outcomes in treating type 2 diabetes (T2D), showcasing the potential of this first-in-class digital Cognitive Behavioral Therapy (CBT) solution to modify disease progression, improve patient health and lower healthcare costs . This presents a win-win for patients, providers, and payers by offering an effective, safe, and accessible treatment option. The digital nature of its products incorporates machine learning and artificial intelligence techniques so they can be widely disseminated to large patient populations yet personalized to the individual patient. The company has the potential to develop a portfolio of PDTs for some of the most prevalent diseases in the U.S. at a fraction of the time and cost of traditional therapeutics. This economic advantage, combined with anticipated reimbursement akin to traditional medicines, positions BTTX's offerings as highly attractive, potentially ensuring wide adoption and sustained revenue growth.

    In an exclusive interview, Dr. Waqaas Al-Siddiq, Founder, Chairman and CEO of Biotricity, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Biotricity is revolutionizing cardiac care with its cutting-edge remote diagnostic and monitoring solutions that cater to a $35 billion total addressable market opportunity. By integrating advanced hardware and proprietary software, Biotricity has established a new paradigm in cardiac care. The Company's robust technology platform and product ecosystem, featuring FDA-cleared smart cardiac monitors, coupled with a comprehensive cloud ecosystem, ensure seamless management of patient health across all stages of cardiac care. Utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by a remarkable 99.2% retention rate and an LTV/CAC ratio of 9. With its strong technological foundation, clear path to profitability, strategic market positioning, and experienced leadership, Biotricity represents a compelling value proposition for investors seeking to capitalize on the rapidly evolving medtech space.

    About Better Therapeutics

    Better Therapeutics is a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address underlying factors that sustain or worsen cardiometabolic diseases. The Company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for T2D, heart disease and other conditions. The CBT delivered by Better Therapeutics' PDTs is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics' clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

    For more information visit: bettertx.com

    About Biotricity

    Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, a sponsored program airing weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    --END--

    SOURCE: RedChip Companies Inc.



    View the original press release on accesswire.com

    Get the next $BTCY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTCY
    $BTTX

    CompanyDatePrice TargetRatingAnalyst
    Biotricity Inc.
    $BTCY
    11/20/2023Buy → Neutral
    H.C. Wainwright
    Biotricity Inc.
    $BTCY
    3/7/2022$5.00Buy
    Lake Street
    Better Therapeutics Inc.
    $BTTX
    11/24/2021$17.00Buy
    Chardan Capital Markets
    Biotricity Inc.
    $BTCY
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    Better Therapeutics Inc.
    $BTTX
    11/10/2021Outperform
    Cowen
    More analyst ratings

    $BTCY
    $BTTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

    REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e

    8/14/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

    Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid

    8/12/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

    FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

    7/17/25 9:33:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    $BTTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perry David P was granted 839,895 shares, increasing direct ownership by 53% to 2,416,634 units (SEC Form 4)

    4 - Better Therapeutics, Inc. (0001832415) (Issuer)

    2/13/24 9:50:33 PM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perry David P was granted 1,471,453 shares, increasing direct ownership by 1,398% to 1,576,739 units (SEC Form 4)

    4 - Better Therapeutics, Inc. (0001832415) (Issuer)

    1/10/24 4:19:25 PM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perry David P was granted 3,750 shares, increasing direct ownership by 4% to 105,286 units (SEC Form 4)

    4 - Better Therapeutics, Inc. (0001832415) (Issuer)

    12/20/23 5:24:37 PM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTCY
    $BTTX
    SEC Filings

    View All

    SEC Form 10-Q filed by Biotricity Inc.

    10-Q - BIOTRICITY INC. (0001630113) (Filer)

    8/14/25 7:01:14 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Biotricity Inc.

    10-K - BIOTRICITY INC. (0001630113) (Filer)

    7/15/25 5:27:01 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form NT 10-K filed by Biotricity Inc.

    NT 10-K - BIOTRICITY INC. (0001630113) (Filer)

    6/30/25 9:20:12 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    $BTTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biotricity downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Biotricity from Buy to Neutral

    11/20/23 7:21:43 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Biotricity with a new price target

    Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00

    3/7/22 9:01:18 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Chardan Capital Markets initiated coverage on Better Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Better Therapeutics with a rating of Buy and set a new price target of $17.00

    11/24/21 7:14:30 AM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTCY
    $BTTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Biotricity Inc.

    SC 13G - BIOTRICITY INC. (0001630113) (Subject)

    8/8/24 6:09:48 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Better Therapeutics Inc. (Amendment)

    SC 13G/A - Better Therapeutics, Inc. (0001832415) (Subject)

    2/13/24 1:00:29 PM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTCY
    $BTTX
    Financials

    Live finance-specific insights

    View All

    Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

    REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e

    8/14/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

    Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14, 2025 at 4:30PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Sid

    8/12/25 8:15:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

    FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

    7/17/25 9:33:00 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $BTCY
    $BTTX
    Leadership Updates

    Live Leadership Updates

    View All

    Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

    One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at improving diabetes outcomes in underserved communities across the United States. Through this partnership, Better Therapeutics is committed to making one million prescriptions of its U.S. Food and Drug Administration (FDA)-authorized product, AspyreRx, available to support

    3/5/24 9:25:00 AM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer

    Industry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, announced today that Diane Gomez-Thinnes joined the company as Chief Commercial Officer starting October 26, 2022. Gomez-Thinnes brings more than two decades of experience in the healthcare industry, leading the commercialization and launch of products spanning the medical device, prescription medicines and consumer health sect

    10/27/22 7:30:00 AM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Better Therapeutics Appoints Frank Karbe as Chief Executive Officer

    Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then. "I'm thrilled to welcome Frank to the Better Therapeutics team," said outgoing CEO Kevin Appelbaum. "Over the past seven years, I have had the privilege of assembling and leading an extraordinarily talented and committed t

    6/7/22 7:30:00 AM ET
    $BTTX
    $EXEL
    $MYOV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)